ERBB2 and breast carcinoma: Since lipid metabolic remodeling as an emerging mechanism participate in resistance to kinase inhibitors [31], we hypothesize that the inhibition of SCD-1 or CD36 might potentiate the effects of current PI3K-targeting agents in breast cancer with resistance to anti-HER2 drugs.